SCHEMBL16922016

SCHEMBL16922016

CN(CCN)C1NC(=O)NC1=O

nearest known ligand 0.38

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31
RGS12 O14924 1/20 0.31
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16921986 0.89 TSHR (0.35) TSHR
SCHEMBL16921880 0.83 TSHR (0.39) TSHRALDH1A1MAPTTDP1
SCHEMBL16921725 0.83 TSHR (0.39) TSHRALDH1A1MAPTTDP1
SCHEMBL16921709 0.80 TSHR (0.36) TSHRALDH1A1MAPT
SCHEMBL15598054 0.79 TSHR (0.34) TSHRRGS12TDP1
SCHEMBL16921838 0.79 ALDH1A1 (0.36) TSHRALDH1A1MAPTTDP1
SCHEMBL16921781 0.79 TSHR (0.41) TSHRALDH1A1MAPT
SCHEMBL16921822 0.76 LMNA (0.35) TSHRALDH1A1MAPT
SCHEMBL16921954 0.74 TSHR (0.38) TSHR
SCHEMBL15597807 0.74 TSHR (0.44) TSHRRGS12TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170327478-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS, INC. 2017-11-16 US disclosed
US-9725426-B2 Cystathionine-γ-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. (US) 2017-08-08 US disclosed
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS SOVA PHARMACEUTICALS, INC. 2015-10-01 US disclosed
US-20150266837-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS, INC. 2015-09-24 US disclosed
US-20150202186-A1 CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN SOVA PHARMACEUTICALS, INC. 2015-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327478-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS CBS, CTH, BHMT TSHR 4585/4885ALDH1A1 954/4885MAPT 2893/4885
US-20150266837-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS CBS, CTH, BHMT TSHR 4585/4885ALDH1A1 954/4885MAPT 2893/4885
US-20150202186-A1 CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN CBS, CTH, MTR TSHR 4817/4885ALDH1A1 1037/4885MAPT 1719/4885
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS HIF1AN, CBS, COXFA4L2 TSHR 4556/4885ALDH1A1 974/4885MAPT 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.